IWA
PGNX

Intercontinental Wealth Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Intercontinental Wealth Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-5,725
Closed -$29K – 433
2019
Q3 		$29K Hold
5,725
– – 0.02% 254
2019
Q2 		$35K Buy
+5,725
New +$27.6K 0.02% 234

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Intercontinental Wealth Advisors's PGNX Position: Q4 2019 in Review

Intercontinental Wealth Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 5,725 shares — an estimated $29K sold.

Intercontinental Wealth Advisors first reported a position in PGNX in Q2 2019 and held it in 2 quarters. The position peaked at $35K in Q2 2019. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

  • Intercontinental Wealth Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
  • Intercontinental Wealth Advisors sold 5,725 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $29K.
  • Intercontinental Wealth Advisors first reported a position in Progenics Pharmaceuticals Inc in Q2 2019 and held it in 2 quarters.
  • Intercontinental Wealth Advisors's Progenics Pharmaceuticals Inc position peaked at $35K in Q2 2019.
  • 128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on Intercontinental Wealth Advisors's 13F filing for Q4 2019, filed 7 Feb 2020.